Conclusion:
Researchers have suggested different drug combination therapies for COVID-19. According to our study, the Ivermectin-Doxycycline combination therapy has a better success of symptomatic relief; shortened recovery duration, reduced adverse effects, and superior patient compliance compared to the Hydroxychloroquine-Azithromycin combination. Based on our outcomes, Ivermectin is a better choice for the treatment of patients with mild to moderate COVID-19 disease. This study has limitations; despite this, we tried to select our study group patients without any major or unstable comorbid condition as far as possible to avoid differences in treatment outcomes among the groups. Further study is required on a larger scale with an increase in the duration of Ivermectin treatment.
sursa:
